John M. Evans - Mar 31, 2022 Form 4 Insider Report for Beam Therapeutics Inc. (BEAM)

Role
CEO, Director
Signature
By: /s/ Christine Bellon, Attorney-in-fact
Stock symbol
BEAM
Transactions as of
Mar 31, 2022
Transactions value $
-$370,088
Form type
4
Date filed
4/4/2022, 08:27 PM
Previous filing
Feb 2, 2022
Next filing
May 2, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BEAM Common Stock Award $0 +56.3K +5.41% $0.00 1.1M Mar 31, 2022 Direct F1, F2
transaction BEAM Common Stock Sale -$370K -6.26K -0.57% $59.11 1.09M Mar 31, 2022 Direct F3
holding BEAM Common Stock 163K Mar 31, 2022 By John M. Evans, III 2018 Irrevocable Trust
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock units ("RSUs") granted to the Reporting Person under the Issuer's 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs vest in four substantially equal annual installments on each of the first four anniversaries of the date of grant, subject to the Reporting Person's continued service with the Company through each vesting date.
F2 Includes 256 shares acquired under the Issuer's employee stock purchase plan on March 31, 2022.
F3 These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the vesting of certain RSUs.